P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma

BACKGROUND: The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains controversial. Here we tested the hypothesis that the activity of alkylators, but not that of bevacizumab, would be associated with the O(6)-methylguanine DNA methyltransferase (MGMT) promoter methyl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Seystahl, K, Hentschel, B, Loew, S, Gramatzki, D, Felsberg, J, Herrlinger, U, Westphal, M, Schackert, G, Thon, N, Schlegel, U, Tatagiba, M, Pietsch, T, Reifenberger, G, Löffler, M, Wick, W, Weller, M
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Poster Presentations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795773/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.343
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi